Literature DB >> 10533727

A new xenograft model of primary central nervous system lymphoma.

M Saini1, M Bellinzona, W Weichhold, M Samii.   

Abstract

The management of primary lymphoma of the central nervous system (PCNSL) remains controversial and patients' outcome dismal. In order to investigate new selective therapeutic strategies in a controlled system, a reproducible model of PCNSL in nude rats was developed and characterized. Human B lymphoma cells (BL2) were implanted in the brain frontal area in New Zealand nude rats through a silastic device sealed to the skull. Fifteen and 30 days post-implantation, animals were sacrificed. An autopsy was performed. Representative brain sections were cut and examined for the presence of lymphoma. Immunohistochemistry was performed for proliferation (MIB1-Ki67), a B-cell marker (L26-CD20), a T-cell marker (UCHL1-CD45RO). The analysis of the brains showed tumor growth in 88% of the rats. No mortality was observed. At autopsy no extracerebral, spinal or cerebellar metastasis were found. Microscopically the brain tumors appeared non-encapsulated, highly vascularized, with a characteristic perivascular and diffuse lymphomatous spread in the parenchyma. Immunohistochemistry showed a marked positivity of the tumor cells for L26. Tumor cells were negative for UCHL1. Mean proliferation rate was 30%. The device was well tolerated and caused no local infection. Controlled studies on PCNSL in animal models are lacking. This PCNSL model in nude rats reproduces the histology and location of human CNS lymphoma. Tumor dimensions are within the resolution limits of CT and MRI and therefore suitable for stereotactic therapy. This model provides a tool to test new chemo and radiotherapeutical strategies in a controlled fashion.

Entities:  

Mesh:

Year:  1999        PMID: 10533727     DOI: 10.1023/a:1006234115968

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Adjuvant chemotherapy for primary lymphoma of the central nervous system.

Authors:  M C Chamberlain; V A Levin
Journal:  Arch Neurol       Date:  1990-10

2.  Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma.

Authors:  R J Ott; M Brada; M A Flower; J W Babich; S R Cherry; B J Deehan
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

3.  Signal transduction pathways mediating astrocyte IL-6 induction by IL-1 beta and tumor necrosis factor-alpha.

Authors:  J G Norris; L P Tang; S M Sparacio; E N Benveniste
Journal:  J Immunol       Date:  1994-01-15       Impact factor: 5.422

4.  MYC oncogene involved in a t(8;22) chromosome translocation is not altered in its putative regulatory regions.

Authors:  L C Showe; R C Moore; J Erikson; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

5.  Diagnosis of primary cerebral lymphoma with particular reference to CT-guided stereotactic biopsy.

Authors:  W Feiden; K Bise; U Steude
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

6.  Monoclonal antibody L26: an antibody that is reactive with normal and neoplastic B lymphocytes in routinely fixed and paraffin wax embedded tissues.

Authors:  A J Norton; P G Isaacson
Journal:  J Clin Pathol       Date:  1987-12       Impact factor: 3.411

7.  SCID/human mouse model of central nervous system lymphoproliferative disease.

Authors:  R Bashir; M Okano; K Kleveland; S Pirrucello; A Masih; W Sanger; R Fordyce-Boyer; D Purtilo
Journal:  Lab Invest       Date:  1991-12       Impact factor: 5.662

8.  Primary central nervous system lymphoma in Japan--a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan.

Authors:  T Hayakawa; K Takakura; H Abe; T Yoshimoto; R Tanaka; K Sugita; H Kikuchi; T Uozumi; T Hori; H Fukui
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Increasing incidence of primary brain lymphoma in the US.

Authors:  N L Eby; S Grufferman; C M Flannelly; S C Schold; F S Vogel; P C Burger
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

Review 10.  Primary central nervous system lymphoma.

Authors:  F H Hochberg; D C Miller
Journal:  J Neurosurg       Date:  1988-06       Impact factor: 5.115

View more
  5 in total

1.  MRI detection of early bone metastases in b16 mouse melanoma models.

Authors:  Karen M Gauvain; Joel R Garbow; Sheng-Kwei Song; Angela C Hirbe; Katherine Weilbaecher
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.

Authors:  Yasuyuki Miyake; Yasushi Okoshi; Takayuki Machino; Shigeru Chiba
Journal:  Int J Hematol       Date:  2010-09-07       Impact factor: 2.490

Review 3.  Advances in the treatment of newly diagnosed primary central nervous system lymphomas.

Authors:  Liren Qian; Ciprian Tomuleasa; Ioan-Alexandru Florian; Jianliang Shen; Ioan-Stefan Florian; Mihnea Zdrenghea; Delia Dima
Journal:  Blood Res       Date:  2017-09-25

4.  Immunomodulatory effects of hemagglutinin- (HA-) modified A20 B-cell lymphoma expanded as a brain tumor on adoptively transferred HA-Specific CD4+ T cells.

Authors:  Valentin P Shichkin; Roman M Moriev
Journal:  ScientificWorldJournal       Date:  2014-02-16

5.  Cerebellar large B-cell lymphoma: a case report.

Authors:  Malik Ghannam; Shaden Mansour; Fareed Jumah; Brent Berry; Albertine Beard
Journal:  J Med Case Rep       Date:  2018-11-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.